BRAF and melanoma: Binimetinib (MEK162) is a potent and selective oral, adenosine triphosphate noncompetitive, small-molecule inhibitor of MEK1/2 approved for the treatment of BRAF mutant melanoma when given in combination with the BRAF inhibitor encorafenib (15, 16).